Published in Clin Exp Immunol on September 01, 1998
Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev (2005) 1.51
CD55 is over-expressed in the tumour environment. Br J Cancer (2001) 1.27
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol (2000) 1.01
Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis. Am J Pathol (2001) 1.00
Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem (2011) 0.82
Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts. PLoS One (2012) 0.81
Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges. Clin Microbiol Rev (2014) 0.79
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med (1986) 3.68
Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (1987) 3.62
Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology (1994) 3.60
Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line. Proc Natl Acad Sci U S A (1988) 3.19
Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology (1992) 3.04
Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry (1986) 2.97
Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol (1995) 2.90
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell (1993) 1.99
The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med (1987) 1.55
Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. Clin Immunol Immunopathol (1993) 1.25
Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol (1994) 1.22
Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol (1989) 1.13
Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Gastroenterology (1996) 1.11
Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J (1994) 1.10
Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res (1993) 1.01
Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci (1996) 1.01
Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother (1996) 0.96
Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest (1995) 0.96
Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol (1996) 0.93
Characterization of vesicles, containing an acylated oligopeptide, released by human colon adenocarcinoma cells. NMR and biochemical studies. FEBS Lett (1989) 0.88
Human glomerular epithelial cells synthesize and secrete the third component of complement. Nephron (1995) 0.85
Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface. J Immunol (1994) 0.84
Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. Gastroenterology (1995) 0.82
Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC). Clin Exp Immunol (1998) 0.79
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell (1988) 9.04
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell (1999) 7.56
The reversible modification regulates the membrane-binding state of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole targeting pathway. J Cell Biol (2000) 7.48
Structure and expression of a cloned cDNA for human interleukin-2. Nature (1983) 7.04
Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J (1998) 6.94
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Identification and characterization of a fibroblast marker: FSP1. J Cell Biol (1995) 6.33
A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 6.28
Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell (1989) 6.11
Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA (2001) 5.43
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 5.15
Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol (2001) 4.81
Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol (1993) 4.76
Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 4.74
A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res (1989) 4.29
The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev (1993) 4.23
Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. Cell (1987) 4.10
Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation (2000) 4.05
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell (1993) 4.04
Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 3.98
Regulation of human interleukin-2 gene: functional DNA sequences in the 5' flanking region for the gene expression in activated T lymphocytes. Cell (1986) 3.88
Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 3.78
Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell (1990) 3.58
Delimitation and properties of DNA sequences required for the regulated expression of human interferon-beta gene. Cell (1985) 3.57
Interferon-beta gene regulation: tandemly repeated sequences of a synthetic 6 bp oligomer function as a virus-inducible enhancer. Cell (1987) 3.51
Immunological nonidentity of heat-labile enterotoxins from human and porcine enterotoxigenic Escherichia coli. Infect Immun (1981) 3.46
Structure of the human interleukin 2 gene. Proc Natl Acad Sci U S A (1983) 3.45
Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: common and unique pathways. Genes Cells (2001) 3.42
The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J (1990) 3.31
Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell (2001) 3.29
Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation (2001) 3.03
Partitioning of Nitrogen among Ribulose-1,5-bisphosphate Carboxylase/Oxygenase, Phosphoenolpyruvate Carboxylase, and Pyruvate Orthophosphate Dikinase as Related to Biomass Productivity in Maize Seedlings. Plant Physiol (1984) 3.02
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Ultra-high resolution SPECT system using four pinhole collimators for small animal studies. J Nucl Med (1995) 2.87
Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun (1994) 2.87
Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol (1992) 2.83
Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med (2000) 2.79
The antisense homology box: a new motif within proteins that encodes biologically active peptides. Nat Med (1995) 2.79
Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol (1992) 2.79
Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell (1997) 2.77
Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med (1992) 2.76
Oxidative degradation of squalene by Arthrobacter species. Appl Microbiol (1975) 2.73
Atomic structure of nanoclusters in oxide-dispersion-strengthened steels. Nat Mater (2011) 2.73
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 2.67
Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol (2000) 2.66
Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol (1992) 2.64
Total en bloc spondylectomy. A new surgical technique for primary malignant vertebral tumors. Spine (Phila Pa 1976) (1997) 2.62
SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell (1999) 2.52
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Endoscopic submucosal dissection for early gastric cancer: results and degrees of technical difficulty as well as success. Endoscopy (2006) 2.48
Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun (1995) 2.42
Use of minilaparotomy in the treatment of colonic cancer. Br J Surg (2001) 2.41
Ampulla cardiomyopathy ('Takotusbo' cardiomyopathy)--reversible left ventricular dysfunction: with ST segment elevation. Jpn Circ J (2000) 2.39
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Activation of IFN-beta element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res (1991) 2.33
Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. J Cell Biol (1995) 2.32
A simple procedure for mass spectrometric microanalysis of 15N in particulate organic matter with special reference to 15N-tracer experiments. Anal Biochem (1977) 2.31
Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature (1984) 2.29
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) (1994) 2.28
Organization and transcription of the gluconate operon, gnt, of Bacillus subtilis. J Biol Chem (1986) 2.23
Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature (1997) 2.20
Recovery of pathogenic measles virus from cloned cDNA. J Virol (2000) 2.19
The NF-kappa B p50 precursor, p105, contains an internal I kappa B-like inhibitor that preferentially inhibits p50. EMBO J (1992) 2.19
Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 2.18
Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut (2007) 2.15
Unique structure of murine interleukin-2 as deduced from cloned cDNAs. Nature (1985) 2.15
Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol (1996) 2.14
CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med (1992) 2.13
Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature (1996) 2.13
Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem (1997) 2.10
A protein kinase similar to MAP kinase activator acts downstream of the raf kinase in Drosophila. Cell (1993) 2.10
Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem (1998) 2.09
In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos (1985) 2.06
Interleukin 2 (IL2) is assigned to human chromosome 4. Somat Cell Mol Genet (1984) 2.05
Genetic organization and diversity of the 3' noncoding region of the hepatitis C virus genome. Virology (1996) 2.04
Accumulation of GTP-bound RhoA during cytokinesis and a critical role of ECT2 in this accumulation. J Biol Chem (2000) 2.04
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Hrs is associated with STAM, a signal-transducing adaptor molecule. Its suppressive effect on cytokine-induced cell growth. J Biol Chem (1997) 2.03
Detection of rotavirus in faeces by latex agglutination. J Immunol Methods (1981) 2.01
Sequence of a cDNA coding for human IRF-1. Nucleic Acids Res (1989) 2.01
Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res (1991) 1.99
The structure of inducing factors for virginiamycin production in Streptomyces virginiae. J Antibiot (Tokyo) (1987) 1.99
Structure of a beta-galactosidase gene of Bacillus stearothermophilus. J Bacteriol (1986) 1.99
Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, Hiroshima-Nagasaki 1949-1969. Cancer (1973) 1.99
A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol (1989) 1.98
The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J Exp Med (1979) 1.97
Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol (1989) 1.97
CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene (1993) 1.95
Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther (2001) 1.95
Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry (2001) 1.94
The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol (1993) 1.93
Closing-opening wedge osteotomy to correct angular kyphotic deformity by a single posterior approach. Spine (Phila Pa 1976) (2001) 1.93
An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol (2000) 1.93
Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses. FEBS Lett (1999) 1.92